大剂量丙种球蛋白静注治疗重症肌无力的疗效研究

Study on High Dose Intravenous Injection of Gamma-globuin in patients with myasthenia gravis

目的 探讨重症肌无力(MG)的免疫状态和临床效果及其在大剂量丙种球蛋白(HDIVIg)静注治疗前后的变化,并观察HDIVIg治疗的临床疗效。方法 用ELISA法检测36例MG患者治疗前后血清乙酰胆碱受体的抗体(AchRAb)和肿瘤坏死因子-α(TNF—α) 变化,并以20例健康者作为对照。比较HDIVIg治疗前后MG患者上述因子的变化。结果 患者治疗有效率为100％,复发率15％。治疗前后AchRAb、TNF-α均有明显的改变。结论 HDIVIg能够改善MG患者的兔疫功能,且显效快、复发率低。

Objectives To investigate the immune statue of myasthenia gravis(MG) before and after treatment with high dose intravenous injection of gamma - globuin(HDIVIg) and to observe clinical effect of HDIVIg.Method Enzyme-linked immunosorbent assay(ELISA)was adopted to measure the change of AchRAb and TNF-a in 40 MC patients before and after reatment with HDIVIg while 20 healther was served as a normal control changes of AchRAb and TNF-a before and after treatment with HDIVIg. Were analyzed comparatively. Results Clinically effective rate of HDIVIg therapy was 100% ,recurrent rate was 15% . The level of AchRAb and TNF-a in patients were significantly lower than those before treatment with HDIVIg .Conclusion HDIVIg can improve the immune function in patients with MG and appers early and recurrence is at lower rate.